Clarivate PLC (CLVT) is not a strong buy for a beginner, long-term investor at this time. The stock shows weak financial performance, bearish technical indicators, and lacks significant positive catalysts. While hedge funds are increasing their positions, the overall sentiment and financial metrics do not support a compelling long-term investment case.
The MACD is positive and expanding, which is a bullish signal. However, the RSI indicates a neutral trend, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 2.655), which could limit further upside in the short term.

Hedge funds are significantly increasing their positions, with a 182.82% increase in buying over the last quarter.
The company faces risks from AI disintermediation and uncertainty around the potential sale of its Life Sciences and Healthcare segment. Analysts have consistently lowered price targets, reflecting concerns about execution and market risks. Additionally, there is no recent news or congress trading data to suggest strong interest or confidence in the stock.
The company's Q4 2025 financials show a decline in revenue (-6.94% YoY), net income (-101.62% YoY), EPS (-100% YoY), and gross margin (-3.83% YoY). These metrics indicate weak financial health and growth trends.
Analysts have lowered price targets significantly, with ratings ranging from Neutral to Underweight. The current price target consensus is below the stock's recent trading price, reflecting bearish sentiment.